Adomas Bunevicius1, Laura Donovan2,3, Jason Sheehan4. 1. Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, 710 W 168th St, New York, NY, 10033, USA. a.bunevicius@yahoo.com. 2. Division of Neuro-Oncology, Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, New York, USA. 3. Herbert Irving Comprehensive Cancer Center, NewYork-Presbyterian Hospital, New York, NY, USA. 4. Department of Neurosurgery, University of Virginia Health System, Charlottesville, VA, 22908, USA.
Abstract
PURPOSE: Health related quality of life (HRQoL) is often used as an outcome measure of cancer treatment. Stereotactic radiosurgery (SRS) is a mainstay treatment of brain metastases (BMs) with constantly improving treatment envelope. The goal of this systematic review was to evaluated HRQoL trajectories after SRS, identify important predictors of HRQoL after SRS, and to evaluate clinical importance of post-SRS HRQoL trajectories of BM patients treated with SRS. METHODS: A systematic literature review according to the PRISMA guidelines analyzing HRQoL trajectories after SRS for BM published in the Pubmed/MEDLINE database before January, 2022. RESULTS: We identified 18 studies that evaluated HRQoL before and at least once after SRS for BMs. The majority of studies were single-institution retrospective series and included patients with different cancer types. Different instruments were used to assess HRQoL. In the majority of studies (n = 10) at group level, there was no significant change in global HRQoL after SRS. Stability, improvement, and deterioration of HRQoL global and subscale scores at individual patient level were common. Post-SRS HRQoL deterioration was predicted by worse functional status, greater number of BMs, delayed SRS, symptomatic BMs, and presence of seizures and cognitive impairment. Shorter post-SRS survival and adverse radiation effects (AREs) were associated with worse HRQoL. CONCLUSIONS: SRS for BMs is often associated with sustained preservation of HRQoL. Individual variation of HRQoL domains after SRS is common. Shorter survival and AREs are associated with worse HRQoL. Worse functional status and greater disease burden predict unfavorable HRQoL trajectories after SRS for BMs.
PURPOSE: Health related quality of life (HRQoL) is often used as an outcome measure of cancer treatment. Stereotactic radiosurgery (SRS) is a mainstay treatment of brain metastases (BMs) with constantly improving treatment envelope. The goal of this systematic review was to evaluated HRQoL trajectories after SRS, identify important predictors of HRQoL after SRS, and to evaluate clinical importance of post-SRS HRQoL trajectories of BM patients treated with SRS. METHODS: A systematic literature review according to the PRISMA guidelines analyzing HRQoL trajectories after SRS for BM published in the Pubmed/MEDLINE database before January, 2022. RESULTS: We identified 18 studies that evaluated HRQoL before and at least once after SRS for BMs. The majority of studies were single-institution retrospective series and included patients with different cancer types. Different instruments were used to assess HRQoL. In the majority of studies (n = 10) at group level, there was no significant change in global HRQoL after SRS. Stability, improvement, and deterioration of HRQoL global and subscale scores at individual patient level were common. Post-SRS HRQoL deterioration was predicted by worse functional status, greater number of BMs, delayed SRS, symptomatic BMs, and presence of seizures and cognitive impairment. Shorter post-SRS survival and adverse radiation effects (AREs) were associated with worse HRQoL. CONCLUSIONS: SRS for BMs is often associated with sustained preservation of HRQoL. Individual variation of HRQoL domains after SRS is common. Shorter survival and AREs are associated with worse HRQoL. Worse functional status and greater disease burden predict unfavorable HRQoL trajectories after SRS for BMs.
Authors: R Soffietti; P Cornu; J Y Delattre; R Grant; F Graus; W Grisold; J Heimans; J Hildebrand; P Hoskin; M Kalljo; P Krauseneck; C Marosi; T Siegal; C Vecht Journal: Eur J Neurol Date: 2006-07 Impact factor: 6.089
Authors: Benjamin H Kann; Henry S Park; Skyler B Johnson; Veronica L Chiang; James B Yu Journal: J Natl Compr Canc Netw Date: 2017-12 Impact factor: 11.908
Authors: Thomas M Churilla; Karla V Ballman; Paul D Brown; Erin L Twohy; Kurt Jaeckle; Elana Farace; Jane H Cerhan; S Keith Anderson; Xiomara W Carrero; Yolanda I Garces; Fred G Barker; Richard Deming; Jesse G Dixon; Stuart H Burri; Caroline Chung; Cynthia Ménard; Volker W Stieber; Bruce E Pollock; Evanthia Galanis; Jan C Buckner; Anthony L Asher Journal: Int J Radiat Oncol Biol Phys Date: 2017-08-05 Impact factor: 7.038
Authors: Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers Journal: Lancet Oncol Date: 2009-10-02 Impact factor: 41.316